Table 2.
Radiation Regimens, Outcomes, and Toxicity Profiles for 15 HFRT Trials
| Author | Daily Fx (Gy) | Total Dose (Gy) | No. Weeks | FU (Mos) | IMRT | bRFS | DM Rate | Acute GI Toxicity, Grade 1–2 | Long-term GI Toxicity, Grade 2–3 |
|---|---|---|---|---|---|---|---|---|---|
| Norkus D et al8 | 3×13; 4.5×4 | 57 | 3.5 | 12 | No | 54.5% 94% | NR | NR 70% | NR |
| Kupelian P et al9 | 2.5 | 70 | 5.5 | 30 | Yes | (88%CF) 87% | NR 82% | (88%CF) | 5% (12%CF) |
| Arcangeli G et al10 | 3.1 | 62 | 4 | 35 | No | (79%CF) | (88%CF) | NR | 16% (11%CF) |
| Arcangeli S et al11 | 3.5 | 56 | 4 | 2 | Yes | NR | NR | 38% | NR |
| Leborgne F et al12 | 3–3.15 | 60–63 | 5 | 66 | No | 89.40% | NR | NR | 4.4% (4.4%CF) |
| Leborgne and Fowler13 | 3–3.15 | 60–63 | 5 | 2–3 | No | NR | NR | 3–4.5%, 3.15–29% (4%CF) | NR |
| Livsey JE et al14 | 3.13 | 50 | 4 | 48 | No | by stage | NR | NR | 5% |
| Rene N et al15 | 3 | 66 | 4.5 | 51 | No | 2.30% | 2.3% | 4% | 1.5% |
| Pollack A et al16 | 2.7 | 70.2 | 5.5 | 3 | Yes | NR | NR | 0% (2%CF) | NR |
| Martin JM et al17 | 3 | 60 | 4 | 38 | Yes | 97% 53% | 4.3% | NR | 4% |
| Yeoh EE et al18 | 2.75 | 55 | 4 | 90 | No | (34%CF) | NR | 2.80% | 2.8% |
| Lukka H et al19 | 2.63 | 52.5 | 5.5 | 67 | No | 60% (53%CF) | NR | NR | 3.2% (3.2%CF) |
| Faria S et al20 | 3 | 66 | 4.5 | 51 | No | 95.4% | 4.4% | NR | 2% |
| Soete G et al21 | 3.5 | 56 | 4 | 2 | Yes | NR | NR | 75% | NR |
| Junius S et al22 | 2.64 | 66 | 5 | 20 | Yes | 8.0% | 0.0% | 47% | 3% |
bFRS, biochemical relapse-free survival; CF, conventional fractionation; DM, distant metastases; Fx, fraction; FU, follow-up; GI, gastrointestinal; HFRT, hypofractionated radiotherapy; IMRT, intensity-modulated radiation therapy; NR, not reported.